Critical Review: PAVmed (PAVM) versus The Competition

PAVmed (NASDAQ:PAVM) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare PAVmed to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends.

Profitability

This table compares PAVmed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
PAVmed Competitors	-278.16%	-150.10%	-21.89%

Volatility & Risk

PAVmed has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, PAVmed’s competitors have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.

Insider and Institutional Ownership

19.9% of PAVmed shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for PAVmed and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	1	1	0	2.00
PAVmed Competitors	4266	10511	18264	826	2.46

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 3,283.69%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.68%. Given PAVmed’s higher probable upside, equities research analysts plainly believe PAVmed is more favorable than its competitors.

Earnings & Valuation

This table compares PAVmed and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PAVmed	$112,000.00	$400,000.00	-0.10
PAVmed Competitors	$1.89 billion	$138.79 million	11.23

PAVmed’s competitors have higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

PAVmed competitors beat PAVmed on 11 of the 13 factors compared.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.